[Phase I study with LH-RH agonist, ICI 118630].
作者信息
Usami M, Kotake T, Sonoda T
出版信息
Hinyokika Kiyo. 1986 Mar;32(3):493-501.
PMID:2942018
Abstract
A single shot of 250 micrograms LH-RH agonist, ICI 118630 (Zoladex), was subcutaneously administered to four healthy male volunteers to investigate the safety and endocrinal effect of the drug. The safety of the drug was confirmed because no clinical problems in vital sign and general clinical tests were observed. The endocrinal reactions of LH, FSH and testosterone in blood were also observed proving that the drug was the LH-RH agonist.
摘要
相似文献
1
[Phase I study with LH-RH agonist, ICI 118630].
Hinyokika Kiyo. 1986 Mar;32(3):493-501.
2
3
Influence of LH-RH agonists on the growth and hormonal environment of breast and prostate cancer.促黄体生成素释放激素激动剂对乳腺癌和前列腺癌生长及激素环境的影响。
Chemioterapia. 1985 Jun;4(3):249-51.
4
5
Comparison of mammalian luteinizing hormone releasing hormone (LH-RH), and of an analog (ICI 118630), on luteinizing hormone and ovarian steroid (progesterone, oestradiol) secretions in laying hens. (Gallus domesticus).
Life Sci. 1986 Aug 11;39(6):541-7. doi: 10.1016/0024-3205(86)90511-4.
6
The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.促黄体生成素释放激素激动剂（ICI 118630，诺雷德）在绝经前晚期乳腺癌中的应用。
Br J Cancer. 1986 May;53(5):629-36. doi: 10.1038/bjc.1986.106.
7
8
[A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies].[一种用于治疗前列腺癌的新型促黄体生成素释放激素激动剂，醋酸戈舍瑞林3个月控释制剂（诺雷德长效注射剂10.8毫克）——临床前及临床研究概述]
Gan To Kagaku Ryoho. 2002 Sep;29(9):1675-87.
9
Zotero 插件